We had a fabulous first SOT with the new company. All our colleagues old and new were so interested to hear about we offer and the successes we have enjoyed in the first few months. What a great ApconiX team effort creating the booth, the literature and the Pandora’s box chocolate giveaway! We had a lot of interest in our posters ‘Development and use of in vitro alternatives by the Pharmaceutical Industry‘ and ‘Target organ profiles in toxicity studies supporting human dosing: does severity progress with longer duration of exposure?‘ I also had fun in the SOT debate arguing against the motion ‘NonClinical Toxicology Testing Predicts Clinical Outcome‘! It was declared a draw; lets see what happens when I argue for the motion at EUROTOX September 2016.
About the Author: Ruth Roberts
Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath. A co-founder of ApconiX, Ruth has 25 years of experience in leading roles in drug safety within large pharma. Ruth is also Chair and Director of Drug Discovery at The University of Birmingham, UK and was previously Global Head of Regulatory Safety at AstraZeneca. With over 140 publications in peer-reviewed journals, she is former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and President of the Academy of Toxicological Sciences. Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development.